Author

Anna Pokorska-Bocci

Observed name: A. Pokorska-Bocci

Institution: Debiopharm (Switzerland)

Observed institution: Debiopharm (Switzerland)

ORCID: 0009-0004-6356-875X

Observed ORCID: 0009-0004-6356-875X

OpenAlex ID: A5091045762

Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results

2019 · I. Matos, L. Goyal, et al. · Annals of Oncology · 4

62eP A large molecular model (LMM)-based predictor of clinical response to the WEE1 inhibitor Debio 0123 + carboplatin therapy

2025 · J. Fuchs, L. Piggott, et al. · ESMO Real World Data and Digital Oncology

Predicting response to naratuximab emtansine, an anti-CD37 antibody-drug conjugate (ADC), in combination with rituximab in Diffuse Large B Cell Lymphoma (DLBCL), by analyzing the spatial arrangement of CD37 and CD20 positive cells using deep learning

2022 · A. Pokorska-Bocci, S. Micallef, et al. · European Journal of Cancer

Works count: 3

Citation count: 4

H-index: 1

I10-index: